If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.

Get Started

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.

Get Started

If You Bought AbbVie Stock 10 Years Ago

The company's stock traded at approximately $64.32 per share 10 years ago. If you had invested $10,000, you could have bought roughly 155 shares. Currently, shares trade at $193.34, meaning your investment's value could have grown to $30,059 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years. 

Don't Miss:

• Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.30/share!
• Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.

AbbVie's dividend yield is currently 3.39%. Over the last 10 years, it has paid about $45.67 in dividends per share, which means you could have made $7,100 from dividends alone. 

Summing up $30,059 and $7,100, we end up with the final value of your investment, which is $37,159. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 271.59%. In comparison, S&P 500 total return for the same period is 221.50%.

What Could The Next 10 Years Bring? 

AbbVie has a consensus rating of "Buy" and a price target of $200.03 based on the ratings of 34 analysts. The price target implies more than a 3% potential upside from the current stock price.

Trending: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. 

On April 25, the company announced its Q1 2025 earnings, posting adjusted EPS of $2.46, up 6.5% year-over-year, and beating the consensus of $2.38, as reported by Benzinga.

The pharmaceutical giant reported sales of $13.34 billion, coming in above the consensus of $12.92 billion.

“AbbVie’s first-quarter results were well ahead of our expectations and reflect an excellent start to the year,” said CEO Robert Michael. “The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term.”

The company raised its full-year 2025 adjusted EPS from the range of $11.99 to $12.19 to $12.09 to $12.29, compared to the consensus of $12.17.

See Also: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it?

How much would it take to earn $100 a month from AbbVie stock. Check out this article by Benzinga to learn more.

Given the historical stock price appreciation and expected upside potential, growth-focused investors may find AbbVie stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.39%.

Read Next:

• Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — Here's How You Can Invest in the Entertainment Market's Next Big Disruptor for Just $998
• ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum.

Image: Shutterstock